Alpha-2 adrenergic activity in perimenopausal women

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Neuropharmacology

Background:

• Perimenopause is associated with potential lipid alterations and increased blood pressure.
• Data on alpha-2 adrenergic activity, which influences norepinephrine secretion, is lacking in perimenopausal women.

Purpose of the Study:

• To investigate the cardiovascular and catecholamine responses to clonidine in perimenopausal women.
• To compare these responses with those of premenopausal women.
• To assess the effect of estrogen replacement therapy on these responses in perimenopausal women.

Main Methods:

• A study involving 15 perimenopausal women (PeriMW) and 13 premenopausal women (PreMW).
• Nine perimenopausal women received 4-month percutaneous estrogen replacement therapy (PeriMWE).
• Cardiovascular parameters (SBP, DBP, HR) and plasma catecholamines (NE, E) were measured before and after clonidine administration.

Main Results:

• Perimenopausal women showed higher basal norepinephrine levels than premenopausal women.
• Clonidine reduced blood pressure and norepinephrine in all groups.
• Heart rate response to clonidine differed, decreasing significantly in premenopausal but not in perimenopausal women, with or without estrogen therapy.

Conclusions:

• Perimenopausal women have increased basal plasma norepinephrine levels.
• Cardiovascular and catecholamine responses to clonidine are similar between perimenopausal and premenopausal women, suggesting normal alpha-2 adrenergic receptor function.
• Estrogen replacement therapy did not significantly alter the cardiovascular or catecholamine response to clonidine in perimenopausal women.